FDA reforms could boost U.S. economy; Novartis arthritis drug gains EU approval;

@FiercePharma: Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article | Follow @FiercePharma

@EricPFierce: Must be some folks sorry Mylan got Agila and they didn't. Hikma says it is getting interest in its injectables biz. Story | Follow @EricPFierce

> Anacor Pharmaceuticals ($ANAC) received upbeat results from the second of two Phase III trials of tavaborole, a topical anti-fungal for the treatment of onychomycosis, a common fungal nail infection in the U.S. Release

> The FDA has granted fast-track status for Cubist Pharmaceuticals' ($CBST) antibiotic ceftolozane/tazobactam to treat bacterial pneumonia and complicated urinary tract infections as well as ceftolozane/tazobactam and surotomycin for complicated intra-abdominal infections (cIAI) and Clostridium difficile-associated diarrhea, respectively. Release

> Novartis' ($NVS) drug Ilaris has been approved in Europe for patients with gout, an often painful type of inflammatory arthritis. Item

> Streamlining FDA processes and cutting inefficiencies could boost U.S. economy. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com : GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Lundbeck gets EU nod for new drug to fight alcohol addiction--$300M tops; no U.S. plans. Story | Follow @JohnCFierce

@RyanMFierce: Alere grabbed some Gates Foundation funding for Tuberculosis and HIV testing products. Release | Follow @RyanMFierce

> As sequestration dawns, FDA supporters scramble to ease woes on drug reviews. Report

> Facebook, Google geeks 'hack' into cancer research problem with mobile game. More

> FDA pins approval on once-monthly version of blockbuster Abilify. Article

Medical Device News

 @FierceMedDev: Boston Scientific posts positive Watchman data. Item | Follow @FierceMedDev

 @MarkHFierce: Fledgling Dx company GeneCentric is raising money to support a lung cancer Dx commercial launch. More | Follow @MarkHFierce

 @DamianFierce: More worry for Intuitive Surgical as the FDA gets involved in the scrutiny of da Vinci robots. Story | Follow @DamianFierce

> Wright finalizes $190M-plus buy of BioMimetic. Story

> AtriCure 2012 losses, revenue grew as market push unfolded. Article

> Alere snags up to $42.2M from Gates Foundation for TB Dx. News

And Finally... EntreMed is raising $10.7 million of securities in a registered direct offering. Release

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.